| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, November 4, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for ... |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Exhibit 99.1 FOR IMMEDIATE RELEASE Arcut is Appoints Rob Scot t, MD to Board of Directors WESTLAKE VILLAGE, Calif., Oct . 28, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on de... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Westlake Village, CA, August 5, 2026—Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the ... |
| 16 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Exhibit 99.1 FOR IMMEDIATE RELEASE Arcutis Expands Board of Directors with Appointment of Chris Peetz WESTLAKE VILLAGE, Calif., July 16, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company fo... |
| 09 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
This Arcutis Biotherapeutics, Inc. (the “Company”) Amended and Restated Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Equity Incentive Plan (the “Plan”) and shall be effective, as a... |
| 06 May 2026 |
8-K: Financial Statements and Exhibits
Westlake Village, CA, May 6, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the q... |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, February 25, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for... |
| 08 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Transition and Consulting Agreement (the “Agreement”) is entered into by and between Bhaskar Chaudhuri (“Director”), and Arcutis Biotherapeutics Inc. (the “Company”), dated as of December 3, 2025 (the “Effective Date”). The purpose ... |
| 28 Oct 2025 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, October 28, 2025 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today outlined its strategy to achiev... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, August 6, 2025 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for th... |
| 17 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
This Arcutis Biotherapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Equity Incentive Plan (the “Plan”) and shall be effective, as amended and restated h... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, May 6, 2025 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the q... |
| 10 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Severance & Change in Control Agreement (the “Agreement”) is entered into by and between Latha Vairavan (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware company (the “Company”), effective as of the date of the Executi... |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, February 25, 2025 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for... |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, November 6, 2024 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for ... |
| 14 Aug 2024 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, August 14, 2024 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for t... |
| 18 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 14, 2024, Arcutis Biotherapeutics, Inc., (the "Company") held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described ... |
| 14 May 2024 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, May 14, 2024 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the ... |
| 10 Apr 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Exhibit 10.2 ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENT This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between David Topper (the “Executive”) and Arcutis Biotherapeutics,... |
Loading...